Key Takeaways
- Revenue scales sharply, profitability follows: H1 FY27 revenue reached ₹48.90 crore, a substantial jump from ₹14.38 crore in H1 FY26, while PAT of ~₹5.08 crore signals the business is converting growth into earnings.
- A balanced portfolio is taking shape: Acute therapy contributes 44% of sales, chronic/semi-chronic 20%, wellness/OTC 20%, and services 16%, reducing dependence on any single vertical.
- Manufacturing integration is the next structural shift: A ₹35 crore CAPEX plant dedicated to self-consumption targets 20% of own formulations, with surplus capacity earmarked for export to rest-of-world markets.
- Management draws a hard line on forward figures: The company explicitly declined to provide any guidance on EBITDA, topline, PAT margin, growth percentages, or peak revenue potential from the manufacturing CAPEX, citing pending compliance.
- What to watch next quarter: Progress toward the 46% geographic coverage target by March 2027, the exchange approval and closure of the ongoing preferential issue, and any update on the manufacturing project report submitted to authorities.
Revenue Growth & Profitability
- H1 scale-up: Revenue from operations grew to ₹48.90 crore in H1 FY27 from ₹14.38 crore in H1 FY26, a jump management described as a significant increase in operating scale.
- Bottom-line conversion: EBITDA stood at ~₹7.68 crore, PBT at ~₹6.83 crore, and PAT at ~₹5.08 crore, results management said provide an encouraging foundation for the next phase of development.
- Receivables and inventory reflect the operating model: Trade receivables of ~₹28.64 crore and inventory of ~₹16.25 crore as of 30th September 2026 are part of the normal cycle in a marketing-led pharmaceutical business where customer credit and stock availability support prescription generation.
- Revenue engine is prescription-led: The company operates on the same model as large pharma companies but at a smaller scale, with revenue primarily generated through prescription generation.
Tejash Hathi: "Revenue growth is an important indicator for the business momentum, but the objective is to convert the momentum into a sustainable, profitable and financially sound operating structure."
Portfolio Mix & Therapy Strategy
- Acute anchors the base: Acute therapy contributed ~44% of sales, forming the largest revenue block and the core of the prescription-generation engine.
- Chronic is young and growing: The chronic/semi-chronic division, introduced in FY25, now contributes 20% of revenue, with management committed to strengthening it further, including cardio-diabetic products.
- Wellness and OTC gaining traction: The wellness/OTC division contributed ~20% of sales and is described as "doing extremely well," remaining a focus area alongside the prescription business.
- Services fill out the mix: The services vertical contributed ~16% of revenue, rounding out a composition management views as balanced across verticals.
- Lead brands span the age spectrum: The core focus covers lead brands mixing chronic and acute therapies, from pediatrics to geriatric, with an emphasis on strengthening presence in tier 2 and tier 3 cities.
Tejash Hathi: "We believe that the quality of growth matters as much as the pace of growth. Our intention is to develop a business that can maintain a sound financial foundation while increasing its scale over time."
Geographic Expansion
- From two states toward half of India: Before listing, the company was present in only 2 states; it is now expanding toward 46% geographic coverage across India by March 2027.
- Pan-India by 2029 is the stated ambition: The long-term objective is a pan-India footprint by 2029, with Aptus products available in every medical store across more than 8.5 lakh pharmacies.
- Phased, quality-first approach: Expansion will follow a phased approach focused on quality of market development and sustainability in each new geography, rather than racing to add territories.
- Talent stability supports the rollout: Employee attrition is below 5–6%, with some employees from 2012 still with the company, providing continuity as the geographic footprint widens.
Tejash Hathi: "Our clear vision and target by 2029 is Pan India presence of our company with our own manufacturing facility as well as expanding our product portfolio."
Manufacturing Integration
- Self-consumption plant, not CDMO: Management was unequivocal that the planned manufacturing facility will be dedicated for self-consumption and will not pursue contract development and manufacturing.
- Output split: The plant will produce 20% of the company's own formulations for self-consumption, with the remaining capacity directed to export to rest-of-world (ROW) countries.
- Initial CAPEX of ₹35 crore: The manufacturing CAPEX is planned at ₹35 crore, with ₹25 crore to be funded from the ongoing preferential issue, and further CAPEX arrangements to be made at the time of execution as needed.
- Detailed project report submitted: A detailed project report has been submitted to the related authorities for the manufacturing project, though management declined to specify a commissioning timeline.
- Margin differential unquantified: When asked whether the manufacturing business margin will be much higher than the current business, management gave a general answer that pharmaceutical industry gross margins are good, without confirming or quantifying any differential.
Tejash Hathi: "Absolutely not. We will not go for the CDMO. The plant will be dedicated for self-consumption."
International & Long-Term Roadmap
- Selective, opportunity-led international push: The strategic roadmap identifies potential opportunities across selected markets in Asia, Africa, and Latin America, with a gradual approach rather than expansion simply to increase country count.
- Integrated pharma business is the end-state: The broader objective is to evolve from the existing platform into a more integrated pharmaceutical business with a stronger domestic footprint and a gradually built international presence.
- Working capital discipline pledged: Priorities include monitoring inventory levels, improving collection efficiency, maintaining appropriate credit discipline, and managing the timing of payments and receipts as revenue increases.
- Cost discipline alongside expansion: Management stated focus will remain on maintaining appropriate cost discipline, improving operating efficiency, and ensuring expansion is supported by sound financial management.
Tejash Hathi: "We believe that sustainable value creation comes from building a strong business step-by-step rather than pursuing expansion without considering the financial and operational implications."
Guidance Policy & Unanswered Questions
- Blanket refusal on forward figures: Management explicitly declined to provide any guidance on EBITDA, topline, PAT margin, or percentage growth for the upcoming years, stating they will disclose guidelines only after compliance.
- Manufacturing CAPEX details withheld: When asked about the peak revenue potential from the ₹35 crore CAPEX and the commissioning timeline, management declined to answer, citing that it would constitute a forward figure.
- Growth expectation stated qualitatively only: Management said the company is "growing very rapidly" and expects "hard work will pay off in the future as well," but declined to attach any percentage to that expectation.
Tejash Hathi: "Sir, let me say first; at present we are not going to give any forward figure. So, at present, we are not giving the guideline regarding the EBITDA or topline or bottom line at present right now."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Geographic coverage | Achieve 46% geographic coverage across India | By March 2027 |
| Pan-India presence | Products available in every medical store across more than 8.5 lakh pharmacies | By 2029 |
| Manufacturing self-sufficiency | Develop approximately 20% of the product portfolio through own manufacturing capabilities | By March 2028 |
| Manufacturing funding | ₹25 crore of the ₹35 crore CAPEX funded from the ongoing preferential issue | Subject to exchange approval |
| Portfolio balance | Strengthen acute and chronic therapy portfolio while developing opportunities across all categories | Ongoing |
Key Metrics
| Metric | H1 FY27 |
|---|---|
| Revenue from operations | ₹48.90 cr (H1 FY27), vs ₹14.38 cr in H1 FY26 |
| Total income | ₹48.96 cr (H1 FY27) |
| EBITDA | ₹7.68 cr (H1 FY27) |
| Profit before tax | ₹6.83 cr (H1 FY27) |
| Profit after tax | ₹5.08 cr (H1 FY27) |
| Acute therapy revenue share | 44% of sales |
| Chronic and semi-chronic therapies revenue share | around 20% of sales |
| Wellness and OTC products revenue share | approximately 20% of sales |
| Sales of services revenue share | around 16% of revenue |
| Total assets | ₹54.55 cr as of 30th September 2026 |
| Inventory | ₹16.25 cr as of 30th September 2026 |
| Trade receivables | ₹28.64 cr as of 30th September 2026 |
| Product portfolio | 300+ formulations |
| Distribution network | 250+ distributors and sub-distributors |
| Retail availability | 45,000+ outlets |
| Doctor coverage | 10,000+ doctors |
| Front-line Medical Representatives on roll | 142 |
| Total on-roll and off-roll professionals | 150+ |
| Sales representatives in distribution networks | 200+ |
| Attrition ratio | Below 5%–6% |
| Planned manufacturing CAPEX (initial phase) | ₹35 cr |
| CAPEX to be funded from preferential issue | ₹25 cr |
| Target geographic coverage by March 2027 | 46% of India |
| Target in-house manufacturing by March 2028 | 20% of product portfolio |
| Target pan-India footprint | 2029 |